<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Neurotrope, Inc.

    Neurotrope, Inc.

    Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...

    Neurotrope is a clinical-stage biotech company ...

    Filing Type:    PU
    DBV Technologies S.A.

    DBV Technologies S.A.

    DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...

    DBV Technologies is developing ViaskinÂŽ, an in...

    Filing Type:    PU
    Reata Pharmaceuticals, Inc.

    Reata Pharmaceuticals, Inc.

    Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...

    Reata is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    Brainstorm Cell Therapeutics Inc.

    Brainstorm Cell Therapeutics Inc.

    BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...

    BrainStorm (NASDAQ:BCLI) is a biotechnology com...

    Filing Type:    PU
    Kazia Therapeutics Limited

    Kazia Therapeutics Limited

    Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...

    Kazia Therapeutics is an oncology-focused biote...

    Filing Type:    PU
    Astellas Pharma, Inc.

    Astellas Pharma, Inc.

    Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...

    Astellas Pharma Inc. is a pharmaceutical compan...

    Filing Type:    PU
    Precision BioSciences, Inc.

    Precision BioSciences, Inc.

    Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...

    Precision BioSciences is dedicated to improving...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of th...

    Nymox Pharmaceutical Corporation specializes in...

    Filing Type:    PU
    MEI Pharma, Inc.

    MEI Pharma, Inc.

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...

    Filing Type:    PU
    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...

    Moleculin Biotech, Inc. is a clinical stage pha...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.